Researchers at The University of Texas MD Anderson Cancer Center have developed a groundbreaking investigational therapy, known as 77A, that enhances the immune system’s ability to combat various blood cancers and solid tumors. This new antibody targets the heat shock protein HSP70, which cancer cells often exploit to evade immune detection. Preliminary findings were presented on December 6, 2025, at the 67th American Society of Hematology (ASH) Annual Meeting.
The study, led by Jun Wei, M.D., Ph.D., an assistant professor of Lymphoma & Myeloma, and principal investigator Robert Z. Orlowski, M.D., Ph.D., demonstrated that 77A significantly boosts the immune response by activating T cells and natural killer (NK) cells. This activation reshapes the tumor microenvironment and supports long-lasting immune responses.
In laboratory models, 77A showed strong antitumor effects, enhancing the efficacy of conventional treatments, including chemotherapy, radiation, and immunotherapies. The antibody’s ability to work effectively in conjunction with other treatments opens up new avenues for patient care. Wei emphasized the therapy’s potential, stating, “There is tremendous promise in the way 77A is capable of rewiring the immune system, enabling it to respond effectively against multiple cancers.”
Mechanism and Future Directions
The mechanism behind 77A lies in its targeting of HSP70, which is known to be overproduced in many blood cancers and solid tumors. This overproduction contributes to a hostile tumor environment that suppresses immune responses and aids cancer cell survival. By neutralizing this protein, 77A enhances the detection and destruction of cancer cells by immune cells, a critical step in effective cancer treatment.
Importantly, early tests with human immune cells have indicated that 77A can also enhance immune responses in healthy donors, paving the way for future clinical trials. This research suggests that the antibody could become a versatile therapeutic option across various cancer types.
Orlowski remarked, “These results give us confidence that 77A could become a versatile immunotherapy. Our next step is to advance a humanized version of this antibody into clinical trials to evaluate its potential in patients across multiple cancer types.”
The humanized version of 77A is currently under development and is expected to move into clinical trials soon, marking a significant step forward in the field of cancer immunotherapy.
The study received support from Blood Cancer United (formerly known as the Leukemia & Lymphoma Society), which underscores the collaborative efforts to advance cancer treatment. A comprehensive list of collaborating authors and their disclosures can be found with the study’s abstract.
As the field of cancer treatment evolves, 77A represents a promising new direction in the quest to improve outcomes for patients facing both blood and solid cancers.
